We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Be Careful With FDA’s New Compliant-Manufacturing Resumption Guidance
Be Careful With FDA’s New Compliant-Manufacturing Resumption Guidance
Jack Garvey, founder and CEO of Compliance Architects, a firm specializing in GMP, quality and compliance services, calls for caution in applying the FDA’s new compliant-manufacturing resumption guidance.